COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($) |
1 Months Ended | ||||
---|---|---|---|---|---|
Mar. 06, 2018 |
Feb. 25, 2015 |
May 17, 2017 |
Feb. 25, 2015 |
Dec. 31, 2018 |
|
Description Of Contribution For Formation | Under the terms of the JV Contract, the JV Partner is required to contribute $290,000 within 30 days of formation, $435,000 12 months later and $725,000 60 months after the date of formation. The Company is required to license certain intellectual property to the China JV. | ||||
Purchase Commitment, Description | On March 6, 2018, the Company signed a distribution agreement with Curexo Inc. for South Korea and as part of this agreement, the Company is obligated to buy a rehabilitative product from Curexo Inc. for $200,000 when this product is fully developed. It is not yet developed at December 31, 2018. | ||||
Royalty on Sales,Percentage | 1.00% | ||||
Bionik Laboratories Corp. [Member] | |||||
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners | 25.00% | ||||
Ginger Capital Investment Holding Inc. [Member] | |||||
Equity Method Investment, Ownership Percentage | 75.00% | ||||
Exchangable Shares [Member] | |||||
Stock Issued During Period, Shares, Issued for Services | 1,753 | ||||
Stock Transferred To Lenders | 2,098 | ||||
Stock to be Reimbursed to Officers | 2,134 | ||||
Stock Issued During Period, Value, Issued for Services | $ 241,185 | ||||
Stock Issued During Period, Value, New Issues | $ 210,323 |
X | ||||||||||
- Definition Description of JV Partner contribution for third company formation. No definition available.
|
X | ||||||||||
- Definition It represents the percentage rate of royalty on sales. No definition available.
|
X | ||||||||||
- Definition Number of stock to be reimbursed to officers during the reporting period. No definition available.
|
X | ||||||||||
- Definition Number of stock transferred to lenders during the reporting period. No definition available.
|
X | ||||||||||
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. No definition available.
|
X | ||||||||||
- Definition Excluding long-term commitments, description of arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers, which may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing (such as penalties) of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. No definition available.
|
X | ||||||||||
- Definition Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. No definition available.
|
X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|